AVITA Medical, Inc. (RCEL)
NASDAQ: RCEL · Real-Time Price · USD
3.960
-0.160 (-3.88%)
Oct 22, 2025, 4:00 PM EDT - Market closed
AVITA Medical Revenue
AVITA Medical had revenue of $18.42M in the quarter ending June 30, 2025, with 21.21% growth. This brings the company's revenue in the last twelve months to $74.88M, up 38.32% year-over-year. In the year 2024, AVITA Medical had annual revenue of $64.25M with 28.14% growth.
Revenue (ttm)
$74.88M
Revenue Growth
+38.32%
P/S Ratio
1.39
Revenue / Employee
$288,015
Employees
260
Market Cap
120.75M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 64.25M | 14.11M | 28.14% |
| Dec 31, 2023 | 50.14M | 15.72M | 45.68% |
| Dec 31, 2022 | 34.42M | 1.40M | 4.23% |
| Dec 31, 2021 | 33.03M | 3.79M | 12.98% |
| Jun 30, 2021 | 29.23M | 14.97M | 104.95% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
RCEL News
- 6 days ago - AVITA Medical Announces CEO Transition - GlobeNewsWire
- 6 days ago - AVITA MEDICAL INVESTIGATION: Bragar Eagel & Squire, P.C. Reminds AVITA Medical Investors to Contact the Firm Regarding the Ongoing Investigation on Behalf of Stockholders - GlobeNewsWire
- 13 days ago - AVITA REMINDER: Bragar Eagel & Squire, P.C. Reminds AVITA Medical Investors to Contact the Firm Regarding the Ongoing Investigation on Behalf of Stockholders - GlobeNewsWire
- 21 days ago - CMS New Technology Add-On Payment Expands Access to RECELL® for Patients with Non-Burn Acute Wounds - GlobeNewsWire
- 4 weeks ago - AVITA Medical: Reimbursement Reset And Breakeven Path By 2026 - Seeking Alpha
- 5 weeks ago - RCEL Investors Have Opportunity to Join AVITA Medical, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
- 6 weeks ago - AVITA Medical, Inc. Investors: Company Investigated by the Portnoy Law Firm - GlobeNewsWire
- 6 weeks ago - AVITA Medical, Inc. (RCEL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha